The Wall Street Resource
The Wall Street Resource
Wall Street Resource, LLC
Adial Pharmaceuticals, Inc. (ADIL), William Stilley, CEO
18 minutes Posted May 3, 2021 at 10:00 am.
0:00
18:17
Download MP3
Show notes

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the treatment and prevention of addictions. The Company’s lead investigational new drug product, AD04, is currently in Phase 3 development as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency and quantity of drinking and heavy drinking with no overt safety concerns.